Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $701.72M.
ENTERPRISE VALUE (EV)
$701.72M
Starling Oncology, Inc.
Market Cap
$657.89M
Enterprise Value (EV)
$701.72M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | $701.72M |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | $625.43M |
| Annexon, Inc. (ANNX)vs › | $660.29M | $485.67M |
| Helus Pharma Inc. (HELP)vs › | $666.95M | $500.78M |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | $539.07M |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | $586.96M |
| Verastem, Inc. (VSTM)vs › | $681.02M | $629.00M |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | $542.03M |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | $490.48M |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | $697.19M |
Market Cap
$657.89M
Total Debt
$77.40M
Cash
$33.56M
Enterprise Value
$701.72M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
